{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:58:01Z","timestamp":1793318281139,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["DRQ-0620"],"award-info":[{"award-number":["DRQ-0620"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Vermont Department of Medicine","id":[{"id":"https:\/\/ror.org\/0155zta11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We recently developed a computational model of cisplatin pharmacodynamics in an endobronchial lung tumor following ultrasound-guided transbronchial needle injection (EBUS-TBNI). The model suggests that it is more efficacious to apportion the cisplatin dose between injections at different sites rather than giving it all in a single central injection, but the model was calibrated only on blood cisplatin data from a single patient. Accordingly, we applied a modified version of our original model in a set of 32 patients undergoing EBUS-TBNI for non-small cell lung cancer (NSCLC). We used the model to predict clinical responses and compared them retrospectively to actual patient outcomes. The model correctly predicted the clinical response in 72% of cases, with 80% accuracy for adenocarcinomas and 62.5% accuracy for squamous-cell lung cancer. We also found a power-law relationship between tumor volume and the minimal dose needed to induce a response, with the power-law exponent depending on the number of injections administered. Our results suggest that current injection strategies may be significantly over- or under-dosing the agent depending on tumor size, and that computational modeling can be a useful planning tool for EBUS-TBNI of cisplatin in lung cancer.<\/jats:p>","DOI":"10.1038\/s41598-021-03849-w","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T06:03:34Z","timestamp":1641535414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A computational modeling approach for dosing endoscopic intratumoral chemotherapy for advanced non-small cell lung cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Vitor","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H. T.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiren J.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Matthew","family":"Kinsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"3849_CR1","volume-title":"Fact Sheet: Cancer","author":"Organization WH","year":"2018","unstructured":"Organization WH. Fact Sheet: Cancer (WHO, 2018)."},{"key":"3849_CR2","volume-title":"SEER Cancer Statistics Review, 1975\u20132014, Based on November 2016 SEER Data Submission","author":"N Howlader","year":"2017","unstructured":"Howlader, N., Noone, A. & Krapcho, M. SEER Cancer Statistics Review, 1975\u20132014, Based on November 2016 SEER Data Submission (National Cancer Institute, 2017)."},{"key":"3849_CR3","doi-asserted-by":"crossref","unstructured":"Khan, F., Anker, C.J., Garrison, G., Kinsey, C.M. Endobronchial ultrasound\u2013guided transbronchial needle injection for local control of recurrent non\u2013small cell lung cancer. Ann. Am. Thorac. Soc. 12, 101\u2013104 (2015).","DOI":"10.1513\/AnnalsATS.201408-358BC"},{"key":"3849_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","volume":"11","author":"F Cappuzzo","year":"2010","unstructured":"Cappuzzo, F. et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 11, 521\u2013529 (2010).","journal-title":"Lancet Oncol."},{"key":"3849_CR5","doi-asserted-by":"crossref","unstructured":"Goldberg, E.P., Hadba, A.R., Almond, B.A., Marotta, J.S. Intratumoral cancer chemotherapy and immunotherapy: Opportunities for nonsystemic preoperative drug delivery. J. Pharm. Pharmacol. 54, 159\u2013180 (2002).","DOI":"10.1211\/0022357021778268"},{"key":"3849_CR6","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1227\/00006123-199512000-00013","volume":"37","author":"KA Walter","year":"1995","unstructured":"Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C. & Brem, H. Intratumoral chemotherapy. Neurosurgery 37, 1129\u20131145 (1995).","journal-title":"Neurosurgery"},{"key":"3849_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.lungcan.2015.10.009","volume":"90","author":"HJ Mehta","year":"2015","unstructured":"Mehta, H. J. et al. Treatment of isolated mediastinal and hilar recurrence of lung cancer with bronchoscopic endobronchial ultrasound guided intratumoral injection of chemotherapy with cisplatin. Lung Cancer 90, 542\u2013547 (2015).","journal-title":"Lung Cancer"},{"key":"3849_CR8","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.21037\/jtd-20-674","volume":"12","author":"CM Kinsey","year":"2020","unstructured":"Kinsey, C. M. et al. Tumor density is associated with response to endobronchial ultrasound-guided transbronchial needle injection of cisplatin. J. Thorac. Dis. 12, 4825 (2020).","journal-title":"J. Thorac. Dis."},{"key":"3849_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2008.03.009","volume":"61","author":"F Celikoglu","year":"2008","unstructured":"Celikoglu, F., Celikoglu, S. I. & Goldberg, E. P. Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer 61, 1\u201312 (2008).","journal-title":"Lung Cancer"},{"key":"3849_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-43270-y","volume":"9","author":"V Mori","year":"2019","unstructured":"Mori, V., Roy, G. S., Bates, J. H. & Kinsey, C. M. Cisplatin pharmacodynamics following endobronchial ultrasound-guided transbronchial needle injection into lung tumors. Sci. Rep. 9, 1\u201310 (2019).","journal-title":"Sci. Rep."},{"key":"3849_CR11","unstructured":"Estepar, R., Jose, S., Ross, J., et al. Chest imaging platform: An open-source library and workstation for quantitative chest imaging. Am. J. Respirat. Crit. Care Med. 191, A4975 (2015)."},{"key":"3849_CR12","unstructured":"Swabb, E.A., Wei, J., Gullino, P.M. Diffusion and convection in normal and neoplastic tissues. Cancer Res. 34, 2814\u20132822 (1974)."},{"key":"3849_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0959-8049(92)90391-E","volume":"28","author":"V Troger","year":"1992","unstructured":"Troger, V., Fischel, J., Formento, P., Gioanni, J. & Milano, G. Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. Eur. J. Cancer 28, 82\u201386 (1992).","journal-title":"Eur. J. Cancer"},{"key":"3849_CR14","doi-asserted-by":"crossref","unstructured":"Kurihara, N., Kubota, T., Hoshiya, Y., et al. Antitumor activity of cis-diamminedichloroplatinum II against human tumor xenografts depends on its area under the curve in nude mice. J. Surg. Oncol. 61, 138\u2013142 (1996).","DOI":"10.1002\/(SICI)1096-9098(199602)61:2<138::AID-JSO9>3.0.CO;2-D"},{"key":"3849_CR15","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013D961 (2012).","journal-title":"Nucleic Acids Res."},{"key":"3849_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer."},{"key":"3849_CR17","first-page":"1197","volume":"12","author":"CM Kinsey","year":"2015","unstructured":"Kinsey, C. M., San Jos\u00e9 Est\u00e9par, R., Wei, Y., Washko, G. R. & Christiani, D. C. Regional emphysema of a non-small cell tumor is associated with larger tumors and decreased survival rates. Ann. Am. Thorac. Soc. 12, 1197\u20131205 (2015).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"3849_CR18","first-page":"260","volume":"11","author":"SI Celikoglu","year":"2004","unstructured":"Celikoglu, S. I., Celikoglu, F. & Goldberg, E. P. Intratumoral cancer chemotherapy through a flexible bronchoscope. J. Bronchol. Intervent. Pulmonol. 11, 260\u2013265 (2004).","journal-title":"J. Bronchol. Intervent. Pulmonol."},{"key":"3849_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/02841869709109228","volume":"36","author":"CG Milross","year":"1997","unstructured":"Milross, C. G. et al. The effect of tumor size on necrosis and polarographically measured pO2. Acta Oncol. 36, 183\u2013189 (1997).","journal-title":"Acta Oncol."},{"key":"3849_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/HP.S133231","volume":"5","author":"JC Forster","year":"2017","unstructured":"Forster, J. C., Harriss-Phillips, W. M., Douglass, M. J. & Bezak, E. A review of the development of tumor vasculature and its effects on the tumor microenvironment. Hypoxia 5, 21 (2017).","journal-title":"Hypoxia"},{"key":"3849_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3892\/ol.2011.420","volume":"3","author":"R Caruso","year":"2012","unstructured":"Caruso, R. et al. Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review. Oncol. Lett. 3, 16\u201318 (2012).","journal-title":"Oncol. Lett."},{"key":"3849_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Investig. 122, 899\u2013910 (2012).","journal-title":"J. Clin. Investig."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03849-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:17:46Z","timestamp":1669303066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03849-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3849"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03849-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JHTB is a consultant for Johnson & Johnson on matters related to this study, and is co-applicant on the patent application \u201cMethods for computational modeling to guide intratumoral therapy.\u201d U.S. Patent Application No. 62\/542,623. Filed: August 8, 2017. CMK is a consultant for Olympus America, Johnson and Johnson, and consultant and equity holder for Quantitative Imaging Solutions. He serves on the steering committee for Nuvaira and the Scientific Advisory Board for Galvanize Therapeutics. He reports grants from the NIH, clinical trial funding through Johnson and Johnson, and is a co-applicant on the patent application \"Methods for computational modeling to guide intratumoral therapy\". U.S. Patent Application No. 62\/542,623. Filed: August 8, 2017.\u201d VM, MJ and HM declare that there are no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}